NCT02040233 (PARSiFAL) is a Phase 2 clinical trial of BAY1067197 (10 mg) in Heart Failure, sponsored by Bayer.

Who is sponsoring NCT02040233?

NCT02040233 is sponsored by Bayer.

What drugs are being tested in NCT02040233?

Interventions in NCT02040233: BAY1067197 (10 mg), BAY1067197, Placebo (10 mg), Placebo.

What condition does NCT02040233 study?

NCT02040233 studies Heart Failure.

Is NCT02040233 still recruiting?

NCT02040233 is currently completed. Last updated 21 June 2019.

Last reviewed 2019-06-21 · How we verify

NCT02040233: PARSiFAL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multiple Dose Study in Heart Failure of BAY 1067197

Completed Phase 2 Last updated 21 June 2019

What this trial tests

Phase 2 trial testing BAY1067197 (10 mg) in Heart Failure in 31 participants. Completed in 2 April 2015.

Timeline

28 January 2014

Primary endpoint
29 January 2015

2 April 2015

Quick facts

Lead sponsor	Bayer
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	31
Start date	28 January 2014
Primary completion	29 January 2015
Estimated completion	2 April 2015
Sites	6 locations across Italy, Netherlands, Germany, Poland

Drugs / interventions tested

BAY1067197 (10 mg) — full drug profile →
BAY1067197 — full drug profile →
Placebo (10 mg) — full drug profile →
Placebo

Conditions studied

Heart Failure — all drugs for Heart Failure →

Sponsor

Bayer — full company profile →

Who can join

Adults 18 to 75, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a study to investigate the safety, tolerability and early effects on cardiac function of the partial A1 agonist BAY1067197 in patients with chronic heart failure. BAY1067197 will be applied once daily over 7 days in addition to standard therapy including a beta-blocker. The aim of the study is to assess if a 7 day treatment with BAY1067197 is well tolerated when given on top of standard therapy for heart failure. Furthermore, the study aims to assess if cardiac function improves in the early course of therapy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting Hypoxia Signaling for Perioperative Organ Injury.
Yuan X, Lee JW, Bowser JL, Neudecker V, et al · · 2018 · cited 79× · PMID 28759485 · DOI 10.1213/ane.0000000000002288
The Adenosinergic System as a Therapeutic Target in the Vasculature: New Ligands and Challenges.
Sousa JB, Diniz C. · · 2017 · cited 17× · PMID 28481238 · DOI 10.3390/molecules22050752
The developmental journey of therapies targeting purine receptors: from basic science to clinical trials.
Han S, Suzuki-Kerr H, Vlajkovic SM, Thorne PR. · · 2022 · cited 9× · PMID 36173587 · DOI 10.1007/s11302-022-09896-w

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02040233 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 21 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02040233.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing